Instrument Inactif

Autres langues Aviragen Therapeutics Inc Nasdaq

Actions

US0906941002

Recherche biotechnologique et médicale

Cours en clôture Nasdaq
- ^USD	-

26/08	Vaxart obtient un nouveau brevet européen pour sa technologie de vaccin oral contre le norovirus	MT
25/08	Vaxart, Inc. annonce la création d'un comité des affaires cliniques et réglementaires et d'un comité d'engagement des actionnaires	CI

Autres langues

26/08	Vaxart Secures New European Patent Covering Oral Norovirus Vaccine Technology
26/08	Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology
25/08	Vaxart, Inc. Announces the Formation of Clinical and Regulatory Affairs Committee and Stockholder Engagement Committee
07/08	Vaxart : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)
06/08	Vaxart, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
06/08	Vaxart Provides Business Update and Reports Second Quarter 2026 Financial Results
30/07	Vaxart to Host Stockholder Fireside Chat on August 7 at 4:30 p.m. ET
28/07	Vaxart, Inc. Announces Reorganization of Committees of the Board of Directors, Effective August 1, 2026
21/07	Vaxart to Participate in BTIG Biotechnology Conference 2026
17/07	Vaxart Announces Results of Annual Meeting of Stockholders
06/07	Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine
06/07	Vaxart Reports Topline 12-Month Safety Data from the 400-Participant Sentinel Safety Cohort of the Phase 2B Clinical Trial of Its Oral Pill Covid-19 Vaccine
01/07	Vaxart Enters Cooperation Agreement with Daniel P. Houle
01/07	Vaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance Enhancements
01/07	Vaxart, Inc. Announces Board and Committee Changes
26/06	Vaxart Publishes Presentation to Shareholders
26/06	Vaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY
25/06	Vaxart Provides Update to Barda Funding Award for Covid-19 Oral Pill Vaccine Trial
25/06	Vaxart Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine Trial
22/06	Daniel P. Houle Issues an Investor Presentation
16/06	Vaxart Provides Information to Shareholders
16/06	Vaxart’s Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual Meeting
16/06	Vaxart Send Letter to Shareholders
15/06	Vaxart to Showcase Oral Vaccine Platform and Strategic Vision at BIO 2026 and Taiwan Biotech Forum
09/06	Daniel Houle Issues Letter to Shareholders of Vaxart